½ÃÀ庸°í¼­
»óǰÄÚµå
1602825

¼¼°èÀÇ Ç×±¸ÅäÁ¦ ½ÃÀå : À¯Çüº°, ¿ëµµº°, ÆÇ¸Å ä³Îº° - ¿¹Ãø(2025-2030³â)

Antiemetic Drugs Market by Type (Acetylcholine, Anticholinergics, Antihistamines), Application (Chemotherapy, Post Operative Surgery, Pregnancy), Sales Channel - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 181 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Ç×±¸ÅäÁ¦ ½ÃÀåÀº 2023³â¿¡ 60¾ï 1,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 59¾ï 2,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, CAGR 7.21%·Î ¼ºÀåÇÒ Àü¸ÁÀ̰í, 2030³â¿¡´Â 97¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Ç×±¸ÅäÁ¦´Â È­ÇÐ ¿ä¹ý, ¼ö¼ú ÈÄ È¸º¹, À§Àå¿° µî ´Ù¾çÇÑ º´¸®¿¡ ÀÚÁÖ ¼ö¹ÝµÇ´Â ¸Þ½º²¨¿ò°ú ±¸Å並 ¿ÏÈ­ÇÏ´Â µ¥ »ç¿ëµÇ´Â ¾à¹°ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á´Â º´¿ø¿¡¼­ ÀçÅà ÀÇ·á±îÁö ±Þ¼º ¹× ¸¸¼º ¿ä±¸¿¡ ´ëÀÀÇÏ´Â ¿©·¯ »óȲ¿¡¼­ ÇʼöÀûÀÔ´Ï´Ù. ÃÖÁ¾ ¿ëµµ¿¡´Â ÁÖ·Î º´¿ø, Áø·á¼Ò, ¼Ò¸Å ¾à±¹, ¿Ü·¡ ȯÀÚ ½Ã¼³ÀÌ Æ÷ÇÔµÇ¾î ¿ëµµÀÇ ³ÐÀ̰¡ µÎµå·¯Áý´Ï´Ù. Ç×±¸ÅäÁ¦ ½ÃÀåÀº ¸¸¼ºÁúȯ À¯º´·ü Áõ°¡, ¿Ü°ú¼ö¼ú Áõ°¡, ¾àÈ¿¸¦ ¿À·¡ Áö¼Ó½ÃŰ°í ºÎÀÛ¿ëÀ» °æ°¨ÇÏ´Â Á¦Á¦ÀÇ Áøº¸ µîÀÇ ¿äÀÎÀÇ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ¼¼°èÀÇ °í·ÉÀÚ Àα¸ÀÇ Áõ°¡´Â, ºñ±³Àû °¨¼ö¼ºÀÌ ³ô±â ¶§¹®¿¡ ¼ö¿ä¸¦ Áõ´ë½Ã۰í ÀÖ½À´Ï´Ù. ¸Þ½º²¨¿ò°ú °ü·ÃµÈ ƯÁ¤ ¼ö¿ëü¸¦ Ç¥ÀûÀ¸·Î ÇÑ °³º°È­ ¾à¹°ÀÇ °³¹ßÀ̳ª »ç¿ë ÆíÀǼº°ú ÄÄÇöóÀ̾𽺠Çâ»óÀ» Á¦°øÇÏ´Â °æÇÇ ÆÐÄ¡¿Í °°Àº »õ·Î¿î Àü´Þ ¹æ¹ýÀÇ Å½±¸¿¡ ÀáÀçÀûÀ¸·Î À¯¸®ÇÑ ±âȸ°¡ µµ»ç¸®°í ÀÖ½À´Ï´Ù. ±×·¯³ª Á¦³×¸¯ ÀǾàǰ Á¦Á¶¾÷ü¿ÍÀÇ ¾ö°ÝÇÑ °æÀï, ½Å¾à °³Ã´ÀÇ °íºñ¿ë, Á¦Ç° Ãâ½Ã¸¦ Á¾Á¾ Áö¿¬½ÃŰ´Â ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç µî ½ÃÀå ¼ºÀåÀº ÇѰ迡 Á÷¸éÇØ ÀÖ½À´Ï´Ù. °Ô´Ù°¡ »ý°­À̳ª Áö¾Ð µî º¸´Ù ÀÚ¿¬½º·´°í ´ëüÀûÀÎ ¸Þ½º²¨¿ò Ä¡·áÁ¦·ÎÀÇ °æÇâÀÌ ³ô¾ÆÁö°í Àֱ⠶§¹®¿¡ ¼ÒºñÀÚÀÇ °ü½ÉÀÌ ¾î±ß³¯ °¡´É¼ºµµ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °úÁ¦¸¦ ȸÇÇÇϱâ À§Çؼ­´Â È¿´ÉÀ» ÃÖÀûÈ­ÇÏ°í ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­ÇÏ´Â Á¦Á¦ÀÇ Çõ½ÅÀÌ ÇʼöÀûÀÔ´Ï´Ù. Á¦¾à»ç¿Í Å×Å©³î·ÎÁö ±â¾÷ÀÇ ÆÄÆ®³Ê½ÊÀ» ¹ßÀü½ÃÅ´À¸·Î½á ¿¹Ãø ºÐ¼®À̳ª AI Áö¿øÀ» ÅëÇÑ °³º°È­ ÀǷḦ ÅëÇØ ȯÀÚ¿¡°Ô ´õ ³ªÀº ¸Þ½º²¨¿ò °ü¸®¸¦ Á¦°øÇÏ´Â µðÁöÅÐ Çコ ¼Ö·ç¼ÇÀÇ ±âȸ°¡ ¿­¸± ¼öµµ ÀÖ½À´Ï´Ù. ÀÌ¿Í °°ÀÌ, Ç×±¸ÅäÁ¦ ½ÃÀå¿¡¼­´Â, ¸Þ½º²¨¿òÀÇ ±ÙÀú¿¡ ÀÖ´Â ¸ÞÄ¿´ÏÁò¿¡ ´ëÇÑ º¸´Ù ±íÀº ÀÌÇØ¿Í, È¿À²ÀûÀÎ ¾à¹°Àü´ÞÀ» À§ÇÑ ½Å±â¼úÀÇ ÅëÇÕ¿¡ ÃÊÁ¡À» ¸ÂÃá °è¼ÓÀûÀÎ ¿¬±¸ °³¹ßÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. °í°´ÀÇ ±âÈ£³ª ±ÔÁ¦ »óȲÀ» Ç×»ó ÆÄ¾ÇÇÏ´Â °ÍÀº, ÀÌ ÁøÈ­ÇÏ´Â ½ÃÀå¿¡¼­ °æÀï·ÂÀ» À¯ÁöÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ À־ Áö±ØÈ÷ Áß¿äÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023³â) 60¾ï 1,000¸¸ ´Þ·¯
¿¹Ãø³â(2024³â) 59¾ï 2,000¸¸ ´Þ·¯
¿¹Ãø³â(2030³â) 97¾ï 9,000¸¸ ´Þ·¯
CAGR(%) 7.21%

½ÃÀå ¿ªÇÐ : ±Þ¼ÓÈ÷ ÁøÈ­ÇÏ´Â Ç×±¸ÅäÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

Ç×±¸ÅäÁ¦ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÅõÀÚ°áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ ȹµæÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ» »Ó¸¸ ¾Æ´Ï¶ó, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¶Ç´Â ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • À§Àå¿°, ±¸Åä, ¸Þ½º²¨¿ò°ú °ü·ÃµÈ ÁúȯÀÇ À¯Çà
    • ¼¼°èÀÇ ¾Ï°ú À§Àå¿°ÀÇ À¯º´·ü Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • Ç×±¸ÅäÁ¦ÀÇ ÀûÀýÇÑ Åõ¿©·®°ú »ç¿ë¹æ¹ý¿¡ °üÇÑ ºÎÁ·ÇÑ Áö½Ä
  • ½ÃÀå ±âȸ
    • »õ·Î¿î Ç×±¸ÅäÁ¦¸¦ µµÀÔÇϱâ À§ÇÑ ¿¬±¸°³¹ß Áõ°¡
    • ÇコÄɾî ÅõÀÚ Áõ°¡¿Í ¿¬±¸°³¹ß Ȱµ¿ÀÇ È°¼ºÈ­
  • ½ÃÀåÀÇ °úÁ¦
    • Ç×±¸ÅäÁ¦¿Í °ü·ÃµÈ ÀÚº» Áý¾àÀûÀÌ°í ½Ã°£ÀÌ ¸¹ÀÌ °É¸®´Â ÇÁ·Î¼¼½º

Porter's Five Forces : Ç×±¸ÅäÁ¦ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲÀÇ °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®¸¦ ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÒ ¼ö ÀÖÀ¸¸ç, º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Ç×±¸ÅäÁ¦ ½ÃÀå¿¡¼­ ¿ÜºÎ·ÎºÎÅÍÀÇ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Ç×±¸ÅäÁ¦ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇϴµ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : Ç×±¸ÅäÁ¦ ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

Ç×±¸ÅäÁ¦ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í °ø±Þ¾÷ü´Â °æÀïÀÌ Ä¡¿­ÇØÁö¸é¼­ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : Ç×±¸ÅäÁ¦ ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Ç×±¸ÅäÁ¦ ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ : Ç×±¸ÅäÁ¦½ÃÀå¿¡¼­ ¼º°øÀ» À§ÇÑ ±æÀ» ±×¸®±â

Ç×±¸ÅäÁ¦ ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í °³¼±À» À§ÇØ ³ë·ÂÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ Á¢±Ù¹ýÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·ÂÀ» Æò°¡ÇÕ´Ï´Ù.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, ¿¬±¸°³¹ß Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð ¹× ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ ¹× ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À² ¹× °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • À§Àå¿°, ±¸Åä, ¸Þ½º²¨¿ò °ü·Ã ÁúȯÀÇ ¸¸¿¬
      • ¼¼°è¿¡¼­ ¾Ï°ú À§Àå¿°ÀÇ ÀÌȯÀ²ÀÌ Áõ°¡
    • ¾ïÁ¦¿äÀÎ
      • Ç×±¸ÅäÁ¦ÀÇ ÀûÀýÇÑ Åõ¿©·®°ú »ç¿ë¹ý¿¡ °üÇÑ ºÎÁ·ÇÑ Áö½Ä
    • ±âȸ
      • »õ·Î¿î Ç×±¸ÅäÁ¦ µµÀÔÀ» ÇâÇÑ ¿¬±¸°³¹ßÀÇ °íÁ¶
      • ÇコÄɾî ÅõÀÚ Áõ°¡¿Í ¿¬±¸°³¹ß Ȱµ¿ÀÇ È°¼ºÈ­
    • °úÁ¦
      • Ç×±¸ÅäÁ¦°ú °ü·ÃµÈ ÀÚº» Áý¾àÇüÀ¸·Î ½Ã°£ÀÌ °É¸®´Â ÇÁ·Î¼¼½º
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå Ç×±¸ÅäÁ¦ ½ÃÀå : À¯Çüº°

  • ¾Æ¼¼Æ¿Äݸ°
  • Ç×Äݸ°Á¦
  • Ç×È÷½ºÅ¸¹ÎÁ¦
  • µµÆÄ¹Î ¼ö¿ëü ±æÇ×Á¦
  • ´º·ÎŰ´Ñ ¼ö¿ëü ±æÇ×Á¦
  • ¼¼·ÎÅä´Ñ ¼ö¿ëü ±æÇ×Á¦

Á¦7Àå Ç×±¸ÅäÁ¦ ½ÃÀå : ¿ëµµº°

  • È­Çпä¹ý
  • ¼ö¼ú ÈÄ ¼ö¼ú
  • ÀÓ½Å

Á¦8Àå Ç×±¸ÅäÁ¦ ½ÃÀå : ÆÇ¸Å ä³Îº°

  • ¿ÀÇÁ¶óÀÎ
    • º´¿ø ¾à±¹
    • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ Ç×±¸ÅäÁ¦ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Ç×±¸ÅäÁ¦ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Ç×±¸ÅäÁ¦ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º(2023³â)
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼® ¹× Á¦¾È

±â¾÷ ¸ñ·Ï

  • Acacia Pharma Limited
  • Akorn Operating Company LLC
  • Algen Healthcare Ltd.
  • Alkem Laboratories Ltd.
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Fresenius Kabi Pte Ltd.
  • Glenmark Pharmaceuticals Limited
  • Global Calcium Private Limited
  • Helsinn Healthcare SA
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Merck KGaA
  • Novartis AG
  • Pax Healthcare
  • Pfizer Inc.
  • Sanofi SA
  • Saphnix Life Sciences
  • Scindia Pharma
  • Sun Pharmaceutical Industries Limited
  • Swastik Life Sciences
  • Teva Pharmaceuticals Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc.
  • Weefsel Pharma
AJY 24.12.13

The Antiemetic Drugs Market was valued at USD 6.01 billion in 2023, expected to reach USD 5.92 billion in 2024, and is projected to grow at a CAGR of 7.21%, to USD 9.79 billion by 2030.

Antiemetic drugs are medications used to relieve nausea and vomiting, symptoms commonly associated with a variety of medical conditions like chemotherapy, post-operative recovery, and gastroenteritis. These treatments are vital across multiple settings, from hospitals to home care, addressing both acute and chronic needs. The end-use scope primarily includes hospitals, clinics, retail pharmacies, and outpatient facilities, highlighting a versatile application range. The market for antiemetic drugs is influenced by factors such as the increasing prevalence of chronic diseases, a rise in surgical procedures, and advancements in drug formulations prolonging their efficacy and reducing side effects. Moreover, the growing elderly population globally amplifies demand due to relatively higher susceptibility. Potentially lucrative opportunities lie in the development of personalized medication targeting specific receptors associated with nausea and the exploration of novel delivery methods, like transdermal patches, that offer ease of use and increased compliance. However, market growth faces limitations, including stiff competition from generic drug manufacturers, high costs of new drug development, and stringent regulatory requirements that often delay product launches. Additionally, the rising trend towards more natural and alternative remedies for nausea, such as ginger and acupressure, could divert consumer interest. To circumvent these challenges, innovation in drug formulations that optimize efficacy and minimize adverse reactions is essential. Developing partnerships between pharmaceutical companies and technology firms may unlock opportunities in digital health solutions offering patients better management of nausea through predictive analytics and AI-aided personalized medicine. As such, the antiemetic drugs market demands continuous research and development, focusing on better understanding the mechanisms underlying nausea and emerging technology integration for efficient drug delivery. Staying abreast of customer preferences and regulatory landscapes will be crucial for companies aiming to maintain competitiveness in this evolving market.

KEY MARKET STATISTICS
Base Year [2023] USD 6.01 billion
Estimated Year [2024] USD 5.92 billion
Forecast Year [2030] USD 9.79 billion
CAGR (%) 7.21%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antiemetic Drugs Market

The Antiemetic Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of gastroenteritis, vomiting and nausea associated diseases
    • Increasing prevalence of cancer and gastroenteritis worldwide
  • Market Restraints
    • Less knowledge regarding the appropriate dosage and usage of anti-emetic drugs
  • Market Opportunities
    • Rising research and development to introduce new anti-emetic drugs
    • Increase in healthcare investments and rising research and development activities
  • Market Challenges
    • Capital intensive and time consuming process associated with anti-emetic drugs

Porter's Five Forces: A Strategic Tool for Navigating the Antiemetic Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antiemetic Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antiemetic Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antiemetic Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antiemetic Drugs Market

A detailed market share analysis in the Antiemetic Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antiemetic Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antiemetic Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antiemetic Drugs Market

A strategic analysis of the Antiemetic Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antiemetic Drugs Market, highlighting leading vendors and their innovative profiles. These include Acacia Pharma Limited, Akorn Operating Company LLC, Algen Healthcare Ltd., Alkem Laboratories Ltd., Cipla Limited, Dr. Reddy's Laboratories Limited, Fresenius Kabi Pte Ltd., Glenmark Pharmaceuticals Limited, Global Calcium Private Limited, Helsinn Healthcare S.A., Hikma Pharmaceuticals PLC, Lupin Limited, Merck KGaA, Novartis AG, Pax Healthcare, Pfizer Inc., Sanofi S.A., Saphnix Life Sciences, Scindia Pharma, Sun Pharmaceutical Industries Limited, Swastik Life Sciences, Teva Pharmaceuticals Industries Ltd., Torrent Pharmaceuticals Ltd., Viatris Inc., and Weefsel Pharma.

Market Segmentation & Coverage

This research report categorizes the Antiemetic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Acetylcholine, Anticholinergics, Antihistamines, Dopamine Receptor Antagonists, Neurokinin Receptor Antagonists, and Serotonin Receptor Antagonists.
  • Based on Application, market is studied across Chemotherapy, Post Operative Surgery, and Pregnancy.
  • Based on Sales Channel, market is studied across Offline and Online. The Offline is further studied across Hospitals Pharmacies and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of gastroenteritis, vomiting and nausea associated diseases
      • 5.1.1.2. Increasing prevalence of cancer and gastroenteritis worldwide
    • 5.1.2. Restraints
      • 5.1.2.1. Less knowledge regarding the appropriate dosage and usage of anti-emetic drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising research and development to introduce new anti-emetic drugs
      • 5.1.3.2. Increase in healthcare investments and rising research and development activities
    • 5.1.4. Challenges
      • 5.1.4.1. Capital intensive and time consuming process associated with anti-emetic drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antiemetic Drugs Market, by Type

  • 6.1. Introduction
  • 6.2. Acetylcholine
  • 6.3. Anticholinergics
  • 6.4. Antihistamines
  • 6.5. Dopamine Receptor Antagonists
  • 6.6. Neurokinin Receptor Antagonists
  • 6.7. Serotonin Receptor Antagonists

7. Antiemetic Drugs Market, by Application

  • 7.1. Introduction
  • 7.2. Chemotherapy
  • 7.3. Post Operative Surgery
  • 7.4. Pregnancy

8. Antiemetic Drugs Market, by Sales Channel

  • 8.1. Introduction
  • 8.2. Offline
    • 8.2.1. Hospitals Pharmacies
    • 8.2.2. Retail Pharmacies
  • 8.3. Online

9. Americas Antiemetic Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Antiemetic Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Antiemetic Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Acacia Pharma Limited
  • 2. Akorn Operating Company LLC
  • 3. Algen Healthcare Ltd.
  • 4. Alkem Laboratories Ltd.
  • 5. Cipla Limited
  • 6. Dr. Reddy's Laboratories Limited
  • 7. Fresenius Kabi Pte Ltd.
  • 8. Glenmark Pharmaceuticals Limited
  • 9. Global Calcium Private Limited
  • 10. Helsinn Healthcare S.A.
  • 11. Hikma Pharmaceuticals PLC
  • 12. Lupin Limited
  • 13. Merck KGaA
  • 14. Novartis AG
  • 15. Pax Healthcare
  • 16. Pfizer Inc.
  • 17. Sanofi S.A.
  • 18. Saphnix Life Sciences
  • 19. Scindia Pharma
  • 20. Sun Pharmaceutical Industries Limited
  • 21. Swastik Life Sciences
  • 22. Teva Pharmaceuticals Industries Ltd.
  • 23. Torrent Pharmaceuticals Ltd.
  • 24. Viatris Inc.
  • 25. Weefsel Pharma
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦